Chemomab Therapeutics (CMMB) Scheduled to Post Quarterly Earnings on Thursday

Chemomab Therapeutics (NASDAQ:CMMB) is set to release its earnings data before the market opens on Thursday, November 14th. Analysts expect Chemomab Therapeutics to post earnings of ($0.20) per share for the quarter.

Chemomab Therapeutics (NASDAQ:CMMB) last issued its earnings results on Wednesday, August 21st. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). During the same quarter last year, the business posted ($0.72) EPS. On average, analysts expect Chemomab Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chemomab Therapeutics Price Performance

CMMB stock opened at $1.43 on Thursday. Chemomab Therapeutics has a 1 year low of $0.42 and a 1 year high of $2.55. The firm has a market capitalization of $20.53 million, a PE ratio of -1.25 and a beta of 0.53. The business has a 50 day simple moving average of $1.64 and a 200-day simple moving average of $1.23.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).